Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Oruka Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for psoriasis and other inflammatory conditions. Its lead products, ORKA-001 and ORKA-002, target IL-23 and IL-17 cytokines, respectively, aiming to improve efficacy and reduce dosing frequency. With a significant market opportunity in the $25 billion psoriasis market, Oruka is positioned to address unmet needs through advanced antibody engineering and strategic partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Oruka Therapeutics, Inc.

1
1
Oruka Therapeutics, Inc. Oruka Therapeutics Reports $31.8 Million Net Loss in Q1 2026, Increases Investment in Clinical Trials

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Oruka Therapeutics, Inc. Oruka Therapeutics Reports $105.4 Million Net Loss and Advances Clinical Trials in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Oruka Therapeutics, Inc. Oruka Therapeutics Reports $30.3 Million Net Loss in Q3 2025, Increases Cash Reserves to $500.9 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Oruka Therapeutics, Inc. Oruka Therapeutics Reports $24.6 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Oruka Therapeutics, Inc. Oruka Therapeutics Reports $20.999 Million Net Loss in Q1 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Oruka Therapeutics, Inc. Oruka Therapeutics Reports $83.7 Million Net Loss and Initiates Phase 1 Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Oruka Therapeutics, Inc. Oruka Therapeutics Reports $410.9M in Cash, $29.4M in Operating Expenses, and Net Loss of $28.6M in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments